House Passes H.R. 2339 Protecting American Lungs and Reversing the Youth Tobacco Epidemic Act
Urge the Senate to bring a companion bill to the floor
Washington, D.C. - February 28, 2020 - The Protecting American Lungs and Reversing the Youth Tobacco Epidemic Act(H.R. 2339) passed the House today. This historic victory marks the first time a house of Congress has voted to prohibit all flavored tobacco products including flavored e-cigarettes, menthol cigarettes and flavored cigars. This legislation comes at a critical point when 6.2 million American middle and high school students used some type of tobacco product last year.
The time is now to urge the senate to commit to end the youth e-cigarette epidemic by bringing a companion bill to the floor.
The Protecting American Lungs and Reversing the Youth Tobacco Epidemic Act (H.R. 2339) takes a comprehensive approach to tackling this issue at multiple levels. The act:
Prohibits all flavored tobacco products, including mint and menthol.
Prohibits online sales of most tobacco products.
Extends advertising restrictions that currently apply to cigarettes and smokeless tobacco to other tobacco products, including e-cigarettes.
Requires the FDA to promptly implement the graphic health warnings on cigarette packs and advertising that are required under the 2009 Tobacco Control Act.
Imposes a federal tax on nicotine used in e-cigarettes. E-cigarettes are currently the only tobacco product not taxed at the federal level despite being the most popular tobacco product among youth. Tobacco taxes have proven to be a highly effective way to reduce use of other tobacco products, especially among price-sensitive youth.
Funds critical prevention and cessation initiatives. The bill funds a national campaign to educate young people, parents and health care providers about the health risks of tobacco products, including e-cigarettes. To help more tobacco users quit, it funds comprehensive tobacco cessation treatment in Community Health Centers, outreach to medically underserved communities, and research to develop and improve cessation treatments.